Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Downregulates the Inflammatory Response in Cutaneous Leishmaniasis Patients Without Interfering in Leishmania braziliensis Killing by Monocytes.
Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Downregulates the Inflammatory Response in Cutaneous Leishmaniasis Patients Without Interfering in Leishmania braziliensis Killing by Monocytes.
复制标题
DOI：
10.3389/fcimb.2022.884237
复制
发表时间：
2022
影响因子：
5.7
通讯作者：
中科院分区：
文献类型：
--
作者：
巴西利什曼原虫感染引起的皮肤利什曼病（CL）患者与组织损伤和溃疡发展相关的炎症反应加剧。有文献记载，五价锑治疗失败的患者比例有所增加。有可能杀死利什曼原虫的抗炎药物的辅助治疗将使CL患者受益。本研究旨在探讨吡格列酮激活过氧化物酶体增殖物激活受体-γ (PPAR-γ)在炎症反应和单核细胞杀伤巴西乳杆菌中的作用。吡格列酮是一种用于治疗糖尿病的口服药物，其主要作用机制是通过激活PPAR-γ， PPAR-γ在多种细胞类型的免疫应答中表达。我们发现吡格列酮激活PPAR-γ可降低CL患者的炎症反应，而不影响单核细胞对巴西l.b iliensis的杀伤。我们的数据表明吡格列酮可以作为巴西乳杆菌引起的CL的辅助治疗。
Patients with cutaneous leishmaniasis (CL) due to Leishmania braziliensis infection have an exacerbated inflammatory response associated with tissue damage and ulcer development. An increase in the rate of patients who fail therapy with pentavalent antimony has been documented. An adjuvant therapy with an anti-inflammatory drug with the potential of Leishmania killing would benefit CL patients. The aim of the present study was to investigate the contribution of peroxisome proliferator-activated receptor-γ (PPAR-γ) activation by pioglitazone in the regulation of the inflammatory response and L. braziliensis killing by monocytes. Pioglitazone is an oral drug used in the treatment of diabetes, and its main mechanism of action is through the activation of PPAR-γ, which is expressed in many cell types of the immune response. We found that activation of PPAR-γ by pioglitazone decreases the inflammatory response in CL patients without affecting L. braziliensis killing by monocytes. Our data suggest that pioglitazone may serve as an adjunctive treatment for CL caused by L. braziliensis.